A systematic review and meta-analysis on the regulation of programmed cell death-1 on T-cells in type 2 diabetes.

In patients living with T2D, immune dysfunction is at least in part due to T-cell exhaustion mediated by the upregulation of PD-1 expression. Therefore, the use of immune checkpoint inhibitors as a therapeutic strategy may be beneficial in restoring immune function in patients with T2D.